May 20, 2021 -- Immunome announced a $4.3 million award from the U.S. Department of Defense (DOD) for the continued development of a monoclonal antibody (mAb) cocktail to combat SARS-CoV-2 and its variants.
IMM-BCP-01 (the cocktail) contains three monoclonal antibodies that bind to nonoverlapping regions of the spike protein with picomolar affinity. The antibodies exhibit combinatorial effects in vitro against multiple SARS-CoV-2 variants, including those exhibiting both increased transmission in the U.S. and resistance to current antibody therapeutics and vaccines, according to Immunome.
The funds were awarded through the DOD's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense in collaboration with the Defense Health Agency. The company received an initial award of $13.3 million from the DOD last year. The bump in funding will support expansion of the clinical study following feedback from the U.S. Food and Drug Administration.